The effects of polyalkylcyanoacrylate nanoparticles on human normal and malignant mesenchymal cells in vitro
References (21)
- et al.
A chemiluminescent assay for mycoplasma in cell cultures
J. Immunol. Methods.
(1985) - et al.
Pharmacokinetics and distribution of a biodegradable drug carrier
Int. J. Pharm.
(1983) - et al.
Effects of leukocyte interfon (E. coli) on human bone sarcoma growth in vitro and the nude mouse
Eur. J. Cancer Clin. Oncol.
(1985) - et al.
Adsorption of monoclonal antibodies to poly-hexylcyanoacrylate nanoparticles and subsequent immunospecific binding to tumor cells in vitro
Int. J. Pharm.
(1983) - et al.
Toxicity of polycyanoacrylate nanoparticles I: free nanoparticles
J. Pharm. Sci.
(1982) Physicochemical characterization of polyacrylic nanoparticles
Int. J. Pharm.
(1983)- et al.
In vivo uptake of polyisobutylcyanoacrylate nanoparticles by rat liver Kuppfer, endothelial and parenchymal cells
J. Pharm. Sci.
(1984) - et al.
Ocular disposition of poly-hexyl-2-cyano-14C-acrylate nanoparticles in the albino rabbit
Int. J. Pharm.
(1985) Selective Toxicity
- et al.
Actinomycin D adsorbed on polymethylcyanoacrylate nanoparticles: increased efficiency against an experimental tumour
Eur. J. Cancer
(1980)
Cited by (21)
Poly(alkyl cyanoacrylate) Nanoparticles as Promising Tools in Cancer Therapeutics
2019, Polymeric Nanoparticles as a Promising Tool for Anti-cancer TherapeuticsTreatment of glioblastoma with poly(isohexyl cyanoacrylate) nanoparticles
2011, International Journal of PharmaceuticsCitation Excerpt :The polymer PIHCA may possess an even better biocompatibility than PBCA, as the toxicity of alkylcyanoacrylates appears to depend on their degradation rate (Gipps et al., 1987; Lherm et al., 1992). Longer alkylcyanoacrylate chains degrade more slowly yielding a reduced toxicity (Gipps et al., 1987; Lherm et al., 1992; Muller et al., 1990). For this reason, in the present study PIHCA-nanoparticles were developed and the anti-tumour efficacy of doxorubicin-loaded PIHCA-nanoparticles and of free doxorubicin in solution was compared in vitro using the rat glioblastoma cell line 101/8.
Colloidal systems for CNS drug delivery
2009, Progress in Brain ResearchCitation Excerpt :These by-products are all potentially harmful to cells as they are small- or medium-sized nonself molecules. In vitro toxicity studies have been performed on several cell lines, namely macrophages (Gaspar, Préat, Opperdoes, & Roland, 1992; Kante et al., 1982), L929 fibroblasts (Huang & Lee, 2006; Lherm et al., 1992), hepatocytes (Fernandez-Urrsuno, Fattal, Feger, Couvreur, & Thérond, 1995; Fernandez-Urrsuno, Fattal, Porquet, Feger, & Couvreur, 1997), cancer cells DC3F (Kubiak, Couvreur, Manil, & Clausse, 1989), mesenchymal cells (Gipps, Groscurth, Kreuter, & Speiser, 1987), Swiss 3T3 cells (Maassen, Fattal, Müller, & Couvreur, 1993; Tseng, Tabata, Hyon, & Ikada, 1990), and murine cerebral microvessels (Vinters & Ho, 1988). Since macrophages are characterized by a high phagocytic propensity, they represent good models to study the toxicity of PACA Np intended for intracellular targeting (Gaspar et al., 1992; Kante et al., 1982).
Protein delivery using nanoparticles based on microemulsions with different structure-types
2008, European Journal of Pharmaceutical SciencesMicroemulsions containing lecithin and sugar-based surfactants: Nanoparticle templates for delivery of proteins and peptides
2008, International Journal of PharmaceuticsSolid lipid nanoparticles for targeted brain drug delivery
2007, Advanced Drug Delivery Reviews